Press Releases

Black patients with early-stage breast cancer who have residual disease after neoadjuvant chemotherapy were more likely to die from the disease than white patients in the same cohort, reports a multidisciplinary team of researchers from Roswell Park Comprehensive Cancer Center. Their findings, newly published in JAMA Network Open, highlight the importance of developing personalized treatment options for people of African descent who develop breast cancer.

Data from a multi-institutional research effort shed light on opportunities to improve the safety of adding immunotherapy to conventional curative therapies, underscoring the importance of close monitoring and multidisciplinary management. Led by a Roswell Park Comprehensive Cancer Center fellow, the work, newly published in The Lancet Oncology, demonstrates that the addition of immune checkpoint inhibition (ICI) to perioperative therapy was associated with increased treatment-related adverse events as well as an increasing trend of fatal toxicity.

Roswell Park's Mary Reid, PhD, spoke alongside Rep. Debbie Wasserman Schultz, representatives from The American Lung Association, GO2 for Lung Cancer and LUNGevity Foundation and lung cancer patient advocates who gathered on Capitol Hill to demand national action to reduce suffering and death from lung cancer.

Three competitive National Cancer Institute grants totaling $13.5 million will support the Roswell Park Comprehensive Cancer Center team leading a multi-institutional effort aimed at improving the potential of immune checkpoint inhibitors, in close collaboration with experts from the University of Rochester’s Wilmot Cancer Institute and Kaiser Permanente Northern California Division of Research.

A phase 1 clinical trial conducted exclusively at Roswell Park shows that a novel treatment regimen can make immunotherapy more effective in patients with metastatic triple-negative breast cancer (mTNBC). Results of the study are reported in The Journal for ImmunoTherapy of Cancer.

Offering access to comprehensive dermatology and treatment of benign disease, the Roswell Park Care Network welcomes physician and longtime faculty member Marcelle Grassi, MD, and her Cheektowaga practice as its newest location.

Research led by Roswell Park Comprehensive Cancer Center and Genome Protection Inc. has detected activity in the “dark genome” that could help transform the diagnosis and treatment of five of the 10 most deadly cancers in the U.S.

Roswell Park Comprehensive Cancer Center and Generate:Biomedicines announce a strategic collaboration to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors. In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.

The Commission on Cancer (CoC), a quality program of the American College of Surgeons, has fully reaccredited Roswell Park Comprehensive Cancer Center for three years. The Commission on Cancer gives recognition to cancer centers that provide multidisciplinary, patient-centered cancer care. Roswell Park is one of the longest-standing CoC programs, having maintained accreditation from the organization continuously since 1931.